- Accesswire•5 days agoLatest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows after President Trump's Comments
NEW YORK, NY / ACCESSWIRE / January 12, 2017 / Biotech and Healthcare stocks were slammed Wednesday as President Donald Trump made some critical remarks against the industries at his first news conference ...
- PR Newswire•last month
LOS ANGELES, Dec. 14, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced today that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of the Board of Directors. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013, and has led the implementation of the Company's clinical and regulatory strategy for the ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, as well as the ICT-121 phase 1 trial in recurrent glioblastoma. The appointment of Dr. Gringeri follows the decision by Andrew Gengos to resign the position of Chief Executive Officer.
- PR Newswire•2 months agoImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016
LOS ANGELES, Nov. 21, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced the presentation of updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ICT-107 is currently being tested in a phase 3 registration trial in patients with newly diagnosed glioblastoma.
IMUC : Summary for ImmunoCellular Therapeutics, Lt - Yahoo Finance
ImmunoCellular Therapeutics, Ltd. (IMUC)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||2.60 - 2.78|
|52 Week Range||1.83 - 14.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-12.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|